Combinatorial targeting of epigenome-modifying enzymes with decitabine and RN-1 synergistically increases HbF
Open Access
- 27 July 2023
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (15) , 3891-3902
Abstract
Increased fetal hemoglobin (HbF) levels reduce the symptoms of sickle cell disease (SCD) and increase the lifespan of patients. Because curative strategies for bone marrow transplantation and gene therapy technologies remain unavailable to a large number of patients, the development of a safe and effective pharmacological therapy that increases HbF offers the greatest potential for disease intervention. Although hydroxyurea increases HbF, a substantial proportion of patients fail to demonstrate an adequate response. Pharmacological inhibitors of DNA methyltransferase (DNMT1) and lysine-specific demethylase 1A (LSD1), 2 epigenome-modifying enzymes associated with the multiprotein corepressor complex recruited to the repressed γ-globin gene, are powerful in vivo inducers of HbF. The hematological side effects of these inhibitors limit feasible clinical exposures. We evaluated whether administering these drugs in combination could reduce the dose and/or time of exposure to any single agent to minimize adverse effects, while achieving additive or synergistic increases in HbF. The DNMT1 inhibitor decitabine (0.5 mg/kg per day) and the LSD1 inhibitor RN-1 (0.25 mg/kg per day) administered in combination 2 days per week produced synergistic increases in F-cells, F-reticulocytes, and γ-globin messenger RNA in healthy baboons. Large increases in HbF and F-cells were observed in healthy, nonanemic, and anemic (phlebotomized) baboons. Combinatorial therapy targeting epigenome-modifying enzymes could thus be a useful strategy for producing larger increases in HbF to modify the clinical course of SCD.Keywords
This publication has 71 references indexed in Scilit:
- Corepressor-dependent silencing of fetal hemoglobin expression by BCL11AProceedings of the National Academy of Sciences, 2013
- Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin inductionNature Medicine, 2013
- Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiationLeukemia, 2012
- Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabineBlood, 2012
- DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymesNucleic Acids Research, 2012
- Nuclear Receptors TR2 and TR4 Recruit Multiple Epigenetic Transcriptional Corepressors That Associate Specifically with the Embryonic β-Type Globin Promoters in Differentiated Adult Erythroid CellsMolecular and Cellular Biology, 2011
- Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzymeNucleic Acids Research, 2010
- The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylationNature Genetics, 2008
- Hemoglobin research and the origins of molecular medicineBlood, 2008
- DNA polymorphisms at the BCL11A , HBS1L-MYB , and β- globin loci associate with fetal hemoglobin levels and pain crises in sickle cell diseaseProceedings of the National Academy of Sciences, 2008